Leerink Swann started coverage on shares of CymaBay Therapeutics Inc. (NASDAQ:CBAY) in a research note issued to investors on Wednesday, MarketBeat.com reports. The brokerage issued an outperform rating and a $12.00 price objective on the biopharmaceutical company’s stock. Leerink Swann also issued estimates for CymaBay Therapeutics’ Q3 2017 earnings at ($0.18) EPS, Q4 2017 earnings at ($0.19) EPS, FY2017 earnings at ($0.85) EPS, FY2018 earnings at ($0.95) EPS and FY2019 earnings at ($1.03) EPS.

Several other equities analysts have also issued reports on the company. Zacks Investment Research lowered CymaBay Therapeutics from a hold rating to a sell rating in a research report on Tuesday, August 22nd. SunTrust Banks, Inc. assumed coverage on CymaBay Therapeutics in a research report on Friday, August 18th. They issued a buy rating and a $15.00 price target for the company. Ifs Securities lowered CymaBay Therapeutics from a strong-buy rating to an outperform rating in a research report on Friday, August 11th. BidaskClub lowered CymaBay Therapeutics from a strong-buy rating to a buy rating in a research report on Thursday, August 3rd. Finally, Piper Jaffray Companies reaffirmed an overweight rating and issued a $12.00 price target on shares of CymaBay Therapeutics in a research report on Tuesday, July 25th. One investment analyst has rated the stock with a sell rating, one has assigned a hold rating and nine have given a buy rating to the stock. The stock has a consensus rating of Buy and an average price target of $12.28.

CymaBay Therapeutics (NASDAQ:CBAY) opened at 6.69 on Wednesday. CymaBay Therapeutics has a 52-week low of $1.15 and a 52-week high of $8.29. The company’s market cap is $292.73 million. The company has a 50-day moving average of $6.72 and a 200-day moving average of $4.70.

CymaBay Therapeutics (NASDAQ:CBAY) last posted its quarterly earnings results on Thursday, August 10th. The biopharmaceutical company reported ($0.31) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.25) by $0.06. On average, equities research analysts expect that CymaBay Therapeutics will post ($0.80) earnings per share for the current fiscal year.

TRADEMARK VIOLATION NOTICE: “CymaBay Therapeutics Inc. (CBAY) Now Covered by Leerink Swann” was first reported by The Cerbat Gem and is the sole property of of The Cerbat Gem. If you are reading this report on another website, it was copied illegally and reposted in violation of US & international trademark & copyright laws. The correct version of this report can be read at https://www.thecerbatgem.com/2017/08/27/cymabay-therapeutics-inc-cbay-now-covered-by-leerink-swann.html.

In other CymaBay Therapeutics news, insider Sujal Shah acquired 10,000 shares of CymaBay Therapeutics stock in a transaction that occurred on Thursday, July 20th. The stock was bought at an average cost of $7.34 per share, for a total transaction of $73,400.00. Following the acquisition, the insider now owns 75,891 shares of the company’s stock, valued at $557,039.94. The purchase was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this link. Also, Director Robert James Wills acquired 5,000 shares of CymaBay Therapeutics stock in a transaction that occurred on Tuesday, August 1st. The stock was acquired at an average price of $6.84 per share, with a total value of $34,200.00. Following the completion of the acquisition, the director now directly owns 25,200 shares in the company, valued at approximately $172,368. The disclosure for this purchase can be found here. Insiders purchased a total of 20,000 shares of company stock valued at $144,750 over the last quarter. 15.10% of the stock is owned by corporate insiders.

A number of large investors have recently added to or reduced their stakes in the company. Acadian Asset Management LLC acquired a new stake in CymaBay Therapeutics during the first quarter valued at approximately $129,000. TFS Capital LLC acquired a new stake in CymaBay Therapeutics during the first quarter valued at approximately $169,000. ClariVest Asset Management LLC acquired a new stake in CymaBay Therapeutics during the first quarter valued at approximately $105,000. Renaissance Technologies LLC increased its stake in CymaBay Therapeutics by 97.6% in the first quarter. Renaissance Technologies LLC now owns 231,949 shares of the biopharmaceutical company’s stock valued at $997,000 after buying an additional 114,549 shares during the last quarter. Finally, Boxer Capital LLC acquired a new stake in CymaBay Therapeutics during the first quarter valued at approximately $3,342,000. Institutional investors own 25.39% of the company’s stock.

About CymaBay Therapeutics

CymaBay Therapeutics, Inc is a clinical-stage biopharmaceutical company. The Company is focused on developing therapies to treat metabolic diseases, including serious rare and orphan diseases. The Company’s product candidates include Arhalofenate, MBX-8025 and MBX-2982. Arhalofenate is used to treat gout.

Analyst Recommendations for CymaBay Therapeutics (NASDAQ:CBAY)

Receive News & Stock Ratings for CymaBay Therapeutics Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for CymaBay Therapeutics Inc. and related stocks with our FREE daily email newsletter.